Skip to main content

Small-Cell Lung Cancer and Mesothelioma

2020 Year in Review - Lung Cancer - Lung Cancer
David Spigel, MD
Chief Scientific Officer; Director
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, TN

Dr David Spigel reviews the results of key studies from 2020 on novel approaches to first- or second-line treatment of SCLC and mesothelioma with both existing and emerging agents.

Related Items
Successful Administration of Alectinib Via Gastrojejunostomy Tube for ALK-Positive Non–Small Cell Lung Cancer: A Case Report
JHOP - June 2027 Vol 17, No 3 published on August 11, 2026 in Case Reports, Lung Cancer, Practical Issues in Pharmacy Management, Targeted Therapies
Improving Amivantamab Premedication Compliance by Implementing a Provider Notification
JHOP - February 2027 Vol 17, No 1 published on July 13, 2026 in Original Research, Lung Cancer, Infusion Issues, Oncology Pharmacy Programs/Protocols, Supportive Care
Outcomes of Early Versus Delayed Initiation of Immunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer
JHOP - August 2026 Vol 16, No 4 published on March 11, 2026 in Original Research, Lung Cancer, Immunotherapy, Adverse Events
Impact of Hyperglycemia During Immune Checkpoint Inhibitor Treatment for Advanced Non–Small Cell Lung Cancer: A Retrospective, Single-Center Study
JHOP - June 2026 Vol 16, No 3 published on February 25, 2026 in Original Research, Checkpoint Inhibitors, Adverse Events, Lung Cancer
The Presence of De Novo EGFR T790M Mutation in a Tyrosine Kinase Inhibitor–Naïve Patient with Lung Adenocarcinoma: Case Report and Review of the Literature
JHOP - December 2022 Vol 12, No 6 published on December 20, 2022 in Case Reports, Lung Cancer, Screening, Tyrosine Kinase Inhibitor
Third-Line Tyrosine Kinase Inhibitor Therapy Results in 16-Year Remission in a Patient with Stage IV Non–Small-Cell Lung Cancer
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in Case Reports, Lung Cancer, Tyrosine Kinase Inhibitor
2022 Midyear Review: Non–Small-Cell Lung Cancer
JHOP - Supplements published on July 21, 2022 in Lung Cancer
First-Line Sotorasib Shows Long-Lasting Responses in Metastatic NSCLC with KRAS Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in AACR Highlights, Lung Cancer
Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Updates, Lung Cancer, Checkpoint Inhibitors
Severe Adverse Events from Immune Checkpoint Inhibitor Therapy a Rare Concerning Side Effect
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer